These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 29155884)
21. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin. Senoo K; Lip GY Stroke; 2016 Jun; 47(6):1665-8. PubMed ID: 27125527 [TBL] [Abstract][Full Text] [Related]
22. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148 [TBL] [Abstract][Full Text] [Related]
23. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448 [TBL] [Abstract][Full Text] [Related]
24. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184 [TBL] [Abstract][Full Text] [Related]
25. The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation. Chan YH; Lee KT; Kao YW; Huang CY; Chen YL; Hang SC; Chu PH PLoS One; 2019; 14(3):e0213517. PubMed ID: 30883567 [TBL] [Abstract][Full Text] [Related]
26. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. An J; Niu F; Lang DT; Jazdzewski KP; Le PT; Rashid N; Meissner B; Mendes R; Dills DG; Aranda G; Bruno A J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26187996 [TBL] [Abstract][Full Text] [Related]
27. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA; J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418 [TBL] [Abstract][Full Text] [Related]
28. Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin. Huang D; Wong CL; Cheng KW; Chan PH; Yue WS; Wong CK; Ho CW; Wong ICK; Chan EW; Siu CW Postgrad Med J; 2018 Apr; 94(1110):207-211. PubMed ID: 29459408 [TBL] [Abstract][Full Text] [Related]
29. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846 [TBL] [Abstract][Full Text] [Related]
30. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948 [TBL] [Abstract][Full Text] [Related]
31. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Hart RG; Pearce LA; Asinger RW; Herzog CA Clin J Am Soc Nephrol; 2011 Nov; 6(11):2599-604. PubMed ID: 21903982 [TBL] [Abstract][Full Text] [Related]
32. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513 [TBL] [Abstract][Full Text] [Related]
33. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310 [TBL] [Abstract][Full Text] [Related]
34. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708 [TBL] [Abstract][Full Text] [Related]
35. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. Williams BA; Evans MA; Honushefsky AM; Berger PB J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746 [TBL] [Abstract][Full Text] [Related]
36. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Apostolakis S; Sullivan RM; Olshansky B; Lip GYH Chest; 2013 Nov; 144(5):1555-1563. PubMed ID: 23669885 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
39. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Nieuwlaat R; Connolly BJ; Hubers LM; Cuddy SM; Eikelboom JW; Yusuf S; Connolly SJ; Thromb Res; 2012 Jun; 129(6):715-9. PubMed ID: 21924760 [TBL] [Abstract][Full Text] [Related]
40. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]